<DOC>
	<DOCNO>NCT00697788</DOCNO>
	<brief_summary>Dexmedetomidine sedative drug approve adult patient , intubate , intensive care unit . We study whether drug cardiovascularly safe pediatric patient recently burn .</brief_summary>
	<brief_title>Dexmedetomidine Cardiovascular Safety Pediatric Burn Patients</brief_title>
	<detailed_description>This ascend dose study evaluate cardiovascular safety dexmedetomidine bolus/infusions acutely burn pediatric patient . The study entail bolus dexmedetomidine , follow 2 hour increase infusion dos . Cardiovascular parameter include EKG , heart rate , oxygen saturation , blood pressure , record .</detailed_description>
	<mesh_term>Burns</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>pediatric patient &gt; 25 % total body surface area ( tbsa ) burn &lt; 90 % tbsa opioid requirement &gt; 0.1 mg/kg/hour morphine ( equivalent ) midazolam requirement &gt; 0.1 mg/kg/hour treatment team determine patient start dexmedetomidine hemodynamically unstable patient ( epinephrine &gt; 1.0 ug/kg/min , levophed &gt; 0.75 ug/kg/min , dopamine &gt; 10 ug/kg/min ) pregnant patient patient history heart block patient congenital heart disease patient significant hepatic dysfunction patient urine output &lt; 0.5 ml/kg/hour [ average ] past 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pediatric</keyword>
	<keyword>burn</keyword>
	<keyword>sedation</keyword>
</DOC>